Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Current Medical Research and Opinion|December 23, 2021
Intra-abdominal <i>Streptococcus agalactiae</i> infection associated with myelofibrosis treated with ruxolitinib: a case report of an atypical clinical presentationJia Chen, Lijuan Pan, Shiqiang Qu, et al.
Leukemia Research Reports|April 23, 2026
Autoimmune myelofibrosis with a <i>TLR8</i> gain-of-function defectShiqiang Qu, Peihong Zhang, Zefeng Xu, et al.
Leukemia & Lymphoma|October 26, 2011
Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center studyShiqiang Qu, Zefeng Xu, Yue Zhang, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|January 30, 2021
Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective StudyNaibo Hu, Tiejun Qin, Xiaoyan Du, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|March 8, 2014
[Clinical efficacy analysis of recombinant human erythropoietin in the treatment of lower-risk myelodysplastic syndromes]Hongli Zhang, Tiejun Qin, Zefeng Xu, et al.
British Journal of Haematology|April 21, 2020
Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutationsShiqiang Qu, Bing Li, Tiejun Qin, et al.
Blood|January 21, 2012
Unique features of primary myelofibrosis in ChineseZefeng Xu, Robert Peter Gale, Yue Zhang, et al.
Leukemia Research Reports|March 25, 2022
<i>ASXL2</i> mutated myelodysplastic syndrome in a novel germline <i>G6b</i> variantShiqiang Qu, Donglei Zhang, Zefeng Xu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 26, 2014
[Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia]Junqing Xu, Zefeng Xu, Tiejun Qin, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|December 4, 2015
[Long- term outcome of thalidomide and cyclosporine in patients with IPSS low/intermediate- 1 myelodysplastic syndromes]Jingya Wang, Tiejun Qin, Zefeng Xu, et al.
Pageof 5